Denali Therapeutics (DNLI) has released an update.
Denali Therapeutics has reported that a recent Phase 2 study of a potential ALS treatment, developed in partnership with Sanofi, failed to achieve its primary goal. Despite this setback, Sanofi plans to share the full findings at a later scientific meeting and will proceed with a separate Phase 2 trial of the same drug for multiple sclerosis patients. The drug in question, SAR443820/DNL788, is a promising oral medication designed to penetrate the brain and inhibit RIPK1, a protein involved in inflammation and cell death.
For further insights into DNLI stock, check out TipRanks’ Stock Analysis page.
